12:01 PM EDT, 06/17/2024 (MT Newswires) -- Natera ( NTRA ) said Monday that it added a new feature to its Prospera Heart test to improve the detection of both acute cellular rejection and antibody-mediated rejection in heart transplant patients.

The company said the new Donor Quantity Score feature in Prospera Heart serves as a "second metric" that improves the accuracy of the test's risk assessment for antibody-mediated rejection and acute cellular rejection.

Shares of Natera ( NTRA ) were up 1.5% in recent trading.

Price: 111.84, Change: +1.64, Percent Change: +1.49